# V1 Empirics Check — moonshotai/kimi-k2.5 (Variant C)

**Model:** moonshotai/kimi-k2.5
**Variant:** C
**Date:** 2026-03-13T16:32:04.064352

---

**Review of "Fair Bills, Slow Care? The Effect of Surprise Billing Laws on Emergency Department Quality"**

---

### 1. Idea Fidelity

The paper partially delivers on the original manifest but omits the key mechanisms and falsification strategies that distinguished the proposed research design. The core staggered difference-in-differences (DiD) analysis using CMS Hospital Compare data (OP-18b and OP-22) is present, and the authors appropriately adopt the Sun-Abraham estimator (a valid alternative to the proposed Callaway-Sant'Anna approach). 

However, the paper fails to execute three critical elements promised in the manifest: (1) **No ERISA falsification test**: The original design proposed using variation in self-insured plan penetration (which is exempt from state laws) as an internal control; this does not appear in the empirical analysis. (2) **No direct PE mechanism tests**: The manifest proposed using CMS cost reports to test for physician-to-NP/PA substitution and direct PE-staffing indicators. Instead, the paper relies solely on for-profit ownership as a coarse proxy, which is neither significant nor conceptually equivalent to PE staffing penetration. (3) **Incomplete temporal coverage**: The manifest included laws effective through 2020 (Colorado, New Mexico, Texas, Washington), but the paper ends in 2018, sacrificing power and variation. The "welfare" analysis is also absent.

---

### 2. Summary

This paper provides the first causal estimates of how state surprise billing laws enacted between 2015–2018 affected emergency department quality, measured by wait times (OP-18b) and left-without-being-seen rates (OP-22). Using a Sun-Abraham staggered DiD estimator on CMS Hospital Compare data for 3,063 hospitals, the author finds precisely estimated null effects: neither wait times nor LWBS rates changed significantly post-reform. The author interprets this as evidence that private equity-backed staffing firms did not cut costs in ways that degraded measurable quality, though ownership heterogeneity tests are inconclusive.

---

### 3. Essential Points

**1. Pre-trend violations invalidate the causal claim.**  
The event-study estimates in Table 4 reveal large, statistically significant negative coefficients at $k = -4$ and $k = -5$ (–2.71 and –6.36 minutes, respectively). These are not "compositional" artifacts to be dismissed in a footnote; they indicate that the 2015 treatment cohort (New York and Connecticut) was on a fundamentally different trajectory than controls prior to treatment. The significant placebo result on OP-20 (door-to-diagnostic time) reinforces that treated states were experiencing differential trends in ED process measures unrelated to surprise billing. The paper cannot claim causal identification without addressing these violations through sensitivity analysis (e.g., Rambachan & Roth bounds) or alternative comparison groups.

**2. Inference is unreliable with only 9 treated clusters.**  
Standard cluster-robust standard errors at the state level require many treated clusters for valid asymptotic inference. With only 9 treated states, the reported confidence intervals are likely anti-conservative. The null result may reflect imprecise estimation rather than a true zero effect. The authors must implement wild cluster bootstrap (Cameron, Gelbach & Miller 2008) or randomization inference to provide valid hypothesis testing.

**3. The mechanism is unsubstantiated.**  
The paper's central contribution rests on the hypothesis that PE-backed staffing firms (TeamHealth, Envision) would cut costs, yet there is no direct evidence linking the laws to staffing changes, billing revenue losses, or PE firm behavior. The ownership heterogeneity analysis (Table 5) is underpowered and insignificant; worse, government hospitals show the *only* marginally significant effect (+1.81 min), which contradicts the PE mechanism. Without the ERISA falsification or staffing substitution analysis proposed in the manifest, the paper cannot distinguish between "no effect on quality" and "no effect on PE firm behavior."

---

### 4. Suggestions

**Address pre-trend violations rigorously.**  
Do not dismiss the $k = -4$ and $k = -5$ coefficients as mechanical. Investigate whether they reflect differential hospital reporting (e.g., urban hospitals entering the CMS data earlier in treated states) or genuine trend differences. Implement the Rambachan & Roth (2023) sensitivity framework to report "breakdown" values of $M$ (maximum pre-trend violation) that would invalidate the null result. If the null is fragile to small violations, the conclusion must be softened substantially. Consider trimming the early pre-period or using a synthetic control approach for the 2015 cohort if parallel trends fail.

**Fix inference with few clusters.**  
Report p-values from wild cluster bootstrap-t procedures (using the `boottest` command in R or Stata) with 9,999 replications. Given the small number of treated states, consider aggregation to the state-year level as a robustness check (though this reduces power, it ensures the clustering structure is credible). Alternatively, use the "cluster wild bootstrap" method of MacKinnon & Webb (2020) specifically designed for few treated clusters.

**Implement the ERISA falsification test.**  
The manifest's most compelling identification strategy—exploiting the fact that ERISA plans are exempt from state laws—remains untested. Obtain data on the share of self-insured enrollment by hospital market (e.g., from the Medical Expenditure Panel Survey or state insurance department filings) and test whether hospitals in markets with higher self-insured shares show attenuated effects. This would both validate the design and provide evidence on mechanism intensity.

**Extend the sample and add mechanism data.**  
Include the 2019–2020 adoptions (CO, NM, TX, WA) to increase treated clusters from 9 to 13 and improve power. Link to CMS Hospital Cost Report data (HCRIS) to test for staffing mix changes (physicians vs. NPs/PAs) and revenue per discharge, which would directly test whether the laws actually constrained PE firm revenue and triggered labor substitution.

**Clarify the economic significance of the null.**  
The paper notes that the 95% CI rules out effects larger than 1.78 minutes (1.2% of the mean). Contextualize this bound: is 1.78 minutes clinically meaningful? Compare to estimates of ED crowding effects from other shocks (e.g., hospital closures, Medicaid expansion). If the literature suggests effects <2 minutes are trivial, emphasize this as "tight bounds on economically irrelevant effects"; if effects >1 minute are considered meaningful, acknowledge that the data cannot rule out small but important degradations.

**Reconsider the placebo interpretation.**  
The significant negative effect on OP-20 (–1.41 minutes, $p<0.001$) is not merely a "flag"—it is evidence of a general improvement in ED efficiency in treated states concurrent with reform. This could indicate concurrent policies (e.g., ACA expansion effects, delivery system reforms in NY/CA) biasing the main estimates downward. Investigate whether states with surprise billing laws also implemented ED throughput initiatives, and control for these confounds or acknowledge the limitation explicitly.

**Ownership vs. PE staffing.**  
Acknowledge that for-profit ownership is a poor proxy for PE staffing penetration. Many for-profit hospitals do not use TeamHealth/Envision, and many nonprofit hospitals do. If direct staffing data are unavailable, use the CMS Open Payments database or Physician Compare to identify hospitals where PE-backed staffing groups have high physician concentration, and test heterogeneity by *predicted* PE exposure rather than ownership.
